[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68:394-424. [2] Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol, 2020. [3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66:115-132. [4] 吴孟超. 肝癌. 北京:人民卫生出版社, 2010:58-61. [5] Miyahara K, Nouso K, Dohi C, et al. Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma. Hepatol Res, 2015,45:986-993. [6] Na K, Kim M, Kim CY, et al. Potential Regulatory Role of Human-Carboxylesterase-1 Glycosylation in Liver Cancer Cell Growth. J Proteome Res, 2020. [7] Zhang S, Cao X, Liu C, et al. N-glycopeptide Signatures of IgA2 in Serum from Patients with Hepatitis B Virus-related Liver Diseases. Mol Cell Proteomics, 2019,18:2262-2272. [8] Zhao T, Jia L, Li J, et al. Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. Front Oncol, 2020,10:496. [9] 陆荫英,赵海涛,程家敏,等. 肝胆肿瘤分子诊断临床应用专家共识. 临床肝胆病杂志, 2020,36:1482-1488. [10] An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res, 2006,5:1626-1635. [11] Kirmiz C, Li B, An HJ, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics, 2007,6:43-55. [12] Liu XE, Desmyter L, Gao CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology, 2007,46:1426-1435. |